Development of therapeutic fusion inhibitor peptides for Measles encephalitis
开发治疗麻疹脑炎的融合抑制肽
基本信息
- 批准号:10414909
- 负责人:
- 金额:$ 35.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-15 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAnimal ModelAntiviral AgentsBindingBiodistributionBrainC-PeptideC-terminalCell membraneCell surfaceCellsCellular ImmunityCenters for Disease Control and Prevention (U.S.)Central Nervous System DiseasesCentral Nervous System InfectionsCessation of lifeChildChild MortalityChimeric ProteinsCholesterolChronicComplicationDataDeveloped CountriesDeveloping CountriesDisadvantagedDiseaseDisease OutbreaksEncephalitisEncephalomyelitisEvaluationEvolutionFatal OutcomeGeneral PopulationGlycoproteinsHIVHemagglutininHerd ImmunityHomeHumanImmuneImmune responseImmune systemImmunityImmunocompetentImmunocompromised HostImmunosuppressionImpairmentIn VitroIncidenceIndividualInfantInfectionInfectious EncephalitisInvestigationLeadLifeLipidsLungMeaslesMeasles virusMediatingMembrane FusionModelingMusN-terminalNational Institute of Allergy and Infectious DiseaseNatureNeuraxisNeuronsParamyxovirusPenetrationPeptidesPeriodicityPersonsPlayPopulationPregnant WomenProcessPublishingResearchRiskRoleSLAM proteinSiteSubacute Sclerosing PanencephalitisTissuesToxic effectTransgenic MiceTreatment EfficacyUnited StatesVaccinatedVaccinationVaccineeVaccinesViralVirusVirus DiseasesWorkanti-viral efficacyattenuated measles virusbasedrug discoveryexperiencefundamental researchimmunogenicityimprovedin vitro testingin vivoin vivo evaluationinfant infectioninhibitorlead candidatelead optimizationmouse modelnectinneglectneutralizing antibodypreclinical developmentpressurepreventprophylacticreceptortherapeutic developmentunvaccinatedviral resistancevirus envelopevirus-induced neurologic disease
项目摘要
Measles (MV) causes disease worldwide despite efforts towards eradication by vaccine, largely because
it is spread so readily between people. MV eradication is currently hindered by the endemic nature of MV
in developing countries and the decreasing rate of vaccination in developed countries. MV disease is
generally self-limited with several life-threatening complications due to the temporary immune
suppression and to the central nervous system (CNS) invasion.
CNS manifestations following MV infection may occur early after infection, in the case of acute
encephalomyelitis.
A second form of MV-induced CNS disease, progressive infectious encephalitis, known as
measles inclusion body encephalitis (MIBE), occurs in immunosuppressed patients 1 to 6 months after
measles infection. This is a lethal sequela that is common in the growing population of
immunocompromised patients, who cannot receive or respond to MV vaccination.
A third form of MV-induced neurological disease – subacute sclerosing panencephalitis (SSPE) –
leads to fatal outcomes years after infection even in the presence of neutralizing antibodies. Data from
recent US outbreaks show that the incidence of SSPE can be as high as 1 every 600 infected infants,
highlighting the significance of this disease also for the immune competent population.
There is no specific therapy for acute or persistent CNS manifestations of measles. We have
applied the results of fundamental research to develop a new antiviral strategy for MV CNS infection,
based on inhibiting membrane fusion during MV entry. A major impetus for this application is our finding
that attachment of lipid moieties to a peptide (termed C-peptide) fusion inhibitor yields three major
advantages: (1) increased potency; (2) ability to follow the virus to the site of fusion activation; and (3)
CNS penetration. We have shown that our prototypical C-peptide prevents lethal encephalitis in a
transgenic mouse model. We propose to assess the therapeutic efficacy of newly improved fusion
inhibitory C-peptides. The strategy will be assessed in vitro, ex vivo, and in vivo using wild-type strain MV
and CNS adapted strains in immune-compromised mice. The proposed work will address two Specific
Aims:
1. To assess the antiviral efficacy of C-peptide fusion inhibitors: in vitro and ex vivo studies.
2. To evaluate therapeutic efficacy of C-peptide fusion inhibitors against MV infection in vivo
and to provide the proof of concept for pre-clinical development.
尽管努力通过疫苗根除麻疹(MV),但它在全球范围内仍会导致疾病,主要是因为
它很容易在人与人之间传播。目前,MV的地方性特性阻碍了根除MV
发展中国家的疫苗接种率和发达国家的疫苗接种率下降。MV病是
由于暂时性免疫,一般有几种危及生命的并发症
抑制和对中枢神经系统(CNS)的侵袭。
MV感染后的中枢神经系统表现可能发生在感染后的早期,如急性
脑脊髓炎。
MV引起的中枢神经系统疾病的第二种形式,即众所周知的进行性传染性脑炎
麻疹包涵体脑炎(MIBE),发生在免疫抑制患者1-6个月后
麻疹感染。这是一种致命的后遗症,在不断增长的中国人口中很常见
免疫功能低下的患者,不能接受MV疫苗接种或对MV疫苗有反应。
MV引起的第三种神经系统疾病-亚急性硬化性全脑炎(SSPE)-
即使在存在中和抗体的情况下,也会在感染数年后导致致命后果。数据来自
美国最近的疫情表明,SSPE的发病率可以高达每600名受感染的婴儿中就有一名,
突出了这种疾病对免疫能力强的人群的重要性。
对于麻疹的急性或持续性中枢神经系统症状,尚无特效治疗方法。我们有
应用基础研究成果开发针对MV CNS感染的新的抗病毒策略,
基于在MV进入过程中抑制膜融合。这一应用的一个主要推动力是我们的发现
将脂质部分附着到多肽(称为C-肽)融合抑制物上会产生三种主要的
优点:(1)增强了效力;(2)能够跟随病毒到达融合激活的位置;以及(3)
中枢神经系统的穿透。我们已经证明,我们的原型C-肽可以预防致命的脑炎
转基因小鼠模型。我们建议评估新改进的融合术的疗效。
抑制性C-肽。该策略将在体外、体外和体内使用野生型毒株MV进行评估。
以及免疫受损小鼠的中枢神经系统适应株。拟议的工作将涉及两个具体的
目标:
1.评价C肽融合抑制剂的抗病毒作用:体外和体外研究。
2.评价C肽融合抑制剂对MV体内感染的治疗效果
为临床前期开发提供概念验证。
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection.
雾化融合抑制肽可保护食蟹猴免受麻疹病毒感染。
- DOI:10.21203/rs.3.rs-1700877/v1
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Reynard,Olivier;Gonzalez,Claudia;Dumont,Claire;Iampietro,Mathieu;Ferren,Marion;LeGuellec,Sandrine;Laurie,Lajoie;Mathieu,Cyrille;Carpentier,Gabrielle;Roseau,Georges;Bovier,FrancescaT;Zhu,Yun;LePennec,Deborah;Montharu,Jérome;A
- 通讯作者:A
Self-assembly Stability Compromises the Efficacy of Tryptophan-Containing Designed Anti-measles Virus Peptides
自组装稳定性损害了含色氨酸设计的抗麻疹病毒肽的功效
- DOI:
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:E. Martínez
- 通讯作者:E. Martínez
Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds.
- DOI:10.3390/v14061186
- 发表时间:2022-05-29
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Inhibition of Measles Viral Fusion Is Enhanced by Targeting Multiple Domains of the Fusion Protein.
- DOI:10.1021/acsnano.1c02057
- 发表时间:2021-08-24
- 期刊:
- 影响因子:17.1
- 作者:Bovier FT;Rybkina K;Biswas S;Harder O;Marcink TC;Niewiesk S;Moscona A;Alabi CA;Porotto M
- 通讯作者:Porotto M
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
- DOI:10.1128/msphere.00571-21
- 发表时间:2021-08-25
- 期刊:
- 影响因子:4.8
- 作者:Stelitano D;Weisberg SP;Goldklang MP;Zhu Y;Bovier FT;Kalantarov GF;Greco G;Decimo D;Franci G;Cennamo M;Portella G;Galdiero M;Mathieu C;Horvat B;Trakht IN;Moscona A;Whitt MA;Porotto M
- 通讯作者:Porotto M
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matteo Porotto其他文献
Matteo Porotto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matteo Porotto', 18)}}的其他基金
Design of fusion inhibitors to block measles host-to-host infection
设计融合抑制剂来阻止麻疹宿主间感染
- 批准号:
10753711 - 财政年份:2023
- 资助金额:
$ 35.44万 - 项目类别:
Design of fusion inhibitors to block measles host-to-host infection
设计融合抑制剂来阻止麻疹宿主间感染
- 批准号:
10457081 - 财政年份:2021
- 资助金额:
$ 35.44万 - 项目类别:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
阻止 SARS-CoV-2 宿主间传播的融合抑制剂
- 批准号:
10457959 - 财政年份:2021
- 资助金额:
$ 35.44万 - 项目类别:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
阻止 SARS-CoV-2 宿主间传播的融合抑制剂
- 批准号:
10668973 - 财政年份:2021
- 资助金额:
$ 35.44万 - 项目类别:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
阻止 SARS-CoV-2 宿主间传播的融合抑制剂
- 批准号:
10237600 - 财政年份:2021
- 资助金额:
$ 35.44万 - 项目类别:
Small molecules to block measles spreading in the central nervous system
小分子阻止麻疹在中枢神经系统中传播
- 批准号:
9986209 - 财政年份:2019
- 资助金额:
$ 35.44万 - 项目类别:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
开发治疗麻疹脑炎的融合抑制肽
- 批准号:
10178126 - 财政年份:2018
- 资助金额:
$ 35.44万 - 项目类别:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
开发治疗麻疹脑炎的融合抑制肽
- 批准号:
9973101 - 财政年份:2018
- 资助金额:
$ 35.44万 - 项目类别:
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors
用于鼻内递送流感融合抑制剂的自组装纳米颗粒
- 批准号:
9441694 - 财政年份:2016
- 资助金额:
$ 35.44万 - 项目类别:
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents
开发新型内体靶向埃博拉病毒进入抑制剂作为抗病毒药物
- 批准号:
9431045 - 财政年份:2016
- 资助金额:
$ 35.44万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.44万 - 项目类别:
Research Grant